Henry Schein (NASDAQ:HSIC) Rating Lowered to “Buy” at Wall Street Zen

Henry Schein (NASDAQ:HSIC) was downgraded by analysts at Wall Street Zen from a “strong-buy” rating to a “buy” rating in a research note issued on Saturday.

A number of other research firms also recently commented on HSIC. Barclays started coverage on shares of Henry Schein in a research note on Monday, December 8th. They set an “overweight” rating and a $86.00 price objective for the company. Leerink Partners restated a “market perform” rating on shares of Henry Schein in a report on Monday. Mizuho upped their price target on shares of Henry Schein from $81.00 to $88.00 and gave the stock a “neutral” rating in a research report on Wednesday, February 25th. JPMorgan Chase & Co. increased their price target on shares of Henry Schein from $78.00 to $92.00 and gave the stock an “overweight” rating in a research note on Wednesday, February 25th. Finally, Wells Fargo & Company lifted their price target on shares of Henry Schein from $76.00 to $87.00 and gave the company an “equal weight” rating in a report on Wednesday, February 25th. Six equities research analysts have rated the stock with a Buy rating, six have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Henry Schein presently has a consensus rating of “Hold” and a consensus price target of $85.58.

Henry Schein Price Performance

HSIC stock opened at $75.57 on Friday. The stock has a market capitalization of $8.67 billion, a price-to-earnings ratio of 23.11, a price-to-earnings-growth ratio of 2.22 and a beta of 0.88. The company has a quick ratio of 0.76, a current ratio of 1.38 and a debt-to-equity ratio of 0.59. Henry Schein has a 52-week low of $60.56 and a 52-week high of $89.29. The stock’s fifty day simple moving average is $78.21 and its 200-day simple moving average is $72.83.

Henry Schein (NASDAQ:HSIC) last released its earnings results on Tuesday, February 24th. The company reported $1.34 EPS for the quarter, beating the consensus estimate of $1.30 by $0.04. Henry Schein had a return on equity of 15.16% and a net margin of 3.02%.The firm had revenue of $3.44 billion during the quarter, compared to analyst estimates of $3.34 billion. During the same period in the prior year, the firm posted $1.19 earnings per share. The business’s quarterly revenue was up 7.7% compared to the same quarter last year. Henry Schein has set its FY 2026 guidance at 5.230-5.370 EPS. Equities research analysts expect that Henry Schein will post 4.74 EPS for the current year.

Insider Transactions at Henry Schein

In other Henry Schein news, Director Kurt P. Kuehn sold 2,844 shares of Henry Schein stock in a transaction that occurred on Tuesday, March 10th. The shares were sold at an average price of $78.96, for a total transaction of $224,562.24. Following the transaction, the director directly owned 15,420 shares of the company’s stock, valued at $1,217,563.20. The trade was a 15.57% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, Director Philip A. Laskawy sold 2,844 shares of Henry Schein stock in a transaction that occurred on Thursday, March 5th. The shares were sold at an average price of $80.36, for a total transaction of $228,543.84. Following the transaction, the director directly owned 21,961 shares in the company, valued at approximately $1,764,785.96. This trade represents a 11.47% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 104,556 shares of company stock worth $8,476,351 over the last 90 days. Company insiders own 1.08% of the company’s stock.

Hedge Funds Weigh In On Henry Schein

A number of hedge funds have recently made changes to their positions in HSIC. CYBER HORNET ETFs LLC purchased a new stake in Henry Schein during the 2nd quarter worth $25,000. MUFG Securities EMEA plc acquired a new stake in Henry Schein in the 2nd quarter valued at $27,000. Flagship Harbor Advisors LLC purchased a new position in Henry Schein in the fourth quarter valued at about $30,000. Federated Hermes Inc. acquired a new position in shares of Henry Schein during the fourth quarter worth about $32,000. Finally, Los Angeles Capital Management LLC acquired a new position in shares of Henry Schein during the fourth quarter worth about $37,000. Hedge funds and other institutional investors own 96.62% of the company’s stock.

About Henry Schein

Henry Schein, Inc is a leading global distributor of healthcare products and services, primarily serving office-based dental, medical and animal health practitioners. The company operates through three principal segments—Schein Dental, Schein Medical and Animal Health—each offering a comprehensive portfolio of consumable products, equipment, instruments and related value-added services. With a focus on improving practice efficiency and patient care, Henry Schein provides everything from dental restorative materials and orthodontic appliances to vaccines, pharmaceuticals and diagnostic devices for physicians, as well as pet health products and veterinary equipment for animal health professionals.

In addition to its broad product offering, Henry Schein delivers a suite of technology and service solutions aimed at streamlining workflows and enhancing clinical outcomes.